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Peroxisome proliferator-activated receptor γ (PPARγ) agonists are commonly used to 
treat cardiovascular diseases, and are reported to have several effects on cardiovascular function 
that may be due to PPARγ-independent signaling events.  Select angiotensin receptor blockers 
(ARBs) interact with and modulate PPARγ activity, thus we hypothesized that a PPARγ agonist 
may exert physiologic effects via the angiotensin II type 1A receptor (AT1AR).  In AT1AR-
overexpressing HEK 293 cells, both angiotensin II (Ang II) and the PPARγ agonist troglitazone 
(Trog) enhanced AT1AR internalization and recruitment of endogenous β-arrestin1/2 (βarr1/2) to 
the AT1AR.  A fluorescence assay to measure diacylglycerol (DAG) accumulation showed that 
although Ang II induced AT1AR-Gq protein-mediated DAG accumulation, Trog had no impact 
on DAG generation.  Trog-mediated recruitment of βarr1/2 was selective to AT1AR as the 
response was prevented by an ARB and Trog-mediated βarr1/2 recruitment to β1-adrenergic 
receptor (β1AR) was not observed.  In isolated mouse cardiomyocytes, Trog increased both % 
and rate of cell shortening to a similar extent as Ang II, effects which were blocked with an 
ARB.  Additionally, these effects were found to be βarr2-dependent, as cardiomyocytes isolated 
from βarr2-KO mice showed blunted contractile responses to Trog.  These findings show for the 
first time that the PPARγ agonist Trog acts at the AT1AR to simultaneously block Gq protein 
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activation and induce the recruitment of βarr1/2, which leads to an increase in cardiomyocyte 
contractility.   
 




 Angiotensin II (Ang II)-mediated activation of the angiotensin type 1A receptor (AT1AR), 
a member of the seven-transmembrane receptor (7TMR) family, leads to the initiation of both Gq 
protein-dependent and -independent signaling cascades.  Gq protein-dependent signaling involves 
2nd messenger generation (e.g. diacylglycerol (DAG) accumulation), ultimately leading to a 
hypertrophic response that can be maladaptive over time, but that can be attenuated via the use of 
angiotensin receptor blockers (ARBs) [1; 2].  G protein-independent signaling involves 
recruitment of β-arrestins 1 and/or 2 (βarr1/2) [3], multifunctional scaffold proteins that are 
involved in numerous cell signaling events including initiation of receptor internalization, 
activation of protein kinase and anti-apoptotic cascades and transactivation of epidermal growth 
factor receptor [3; 4; 5].  β-arrestin-dependent signaling has been shown to be both 
physiologically relevant and beneficial in the cardiovascular system.  In cardiomyocytes, β-
arrestin signaling mediates protection against chronic sympathetic stimulation [6] and increases 
contractility in response to AT1AR stimulation [7].  Additionally, β-arrestin signaling has been 
shown to activate anti-apoptotic pathways downstream of AT1AR in vascular smooth muscle 
cells [5].  Thus, an agent that acts selectively at the AT1AR to induce beneficial β-arrestin 
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signaling without increasing detrimental Gq protein activity could effective in the treatment of 
cardiovascular disorders. 
Recent studies have shown that synthetic agonists for the transcription factor peroxisome 
proliferator-activated receptor γ (PPARγ) oppose Ang II-mediated effects, reducing the 
hypertrophic response of cardiomyocytes to administration of Ang II as well as decreasing Ang 
II-mediated signaling in blood vessels and subsequent development of hypertension [8; 9; 10; 
11].  Synthetic agonists for PPARγ are typically used in the treatment of Type II diabetes to 
increase insulin sensitivity [12].  These agents have been shown experimentally and clinically to 
improve cardiovascular function via increased vascular reactivity and cardiac function, decreased 
inflammation and reduced visceral fat storage (as reviewed in [13]).    The mechanisms by which 
PPARγ agonists oppose Ang II-mediated signaling are not fully understood, but may be 
independent of PPARγ itself.  In fact, PPARγ agonists such as troglitazone (Trog) have been 
shown to induce acute intracellular signaling responses independent of the effects of PPARγ on 
transcriptional processes, though a role for 7TMRs in mediating these responses has not been 
explored [14; 15].   
While PPARγ agonists have been shown to oppose Ang II signaling, a subset of 
angiotensin receptor blockers (ARBs) have been shown to be selective PPARγ modulators 
(SPARRMs), increasing gene transcription and modulating metabolic pathways to reduce 
glucose and triglyceride levels and increase insulin sensitivity [16; 17; 18].  Since PPARγ 
agonists can induce PPARγ-independent signaling, and select ARBs can activate PPARγ, we 
tested the hypothesis that PPARγ agonists activate AT1AR signaling.  Here, we show that Trog 
stimulates the AT1AR to induce endogenous βarr1/2 recruitment and AT1AR internalization 
without Gq protein activation.  Moreover, cardiomyocyte contractility is increased in response to 
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Trog, an effect that is sensitive to both an ARB and βarr2 expression, indicating that activation of 
AT1AR-β-arrestin-mediated signaling is a mechanism by which PPARγ agonists can induce 
PPARγ-independent physiologic effects. 
 
Materials and Methods 
Materials.  HEK 293 cells stably expressing hemagglutinin-tagged AT1AR (HA-AT1AR cells), 
the plasmid construct for monomeric cyan fluorescent protein (mCFP)/mYFP-tagged 
diacylglycerol reporter (DAGR) and βarr2 knockout mice were kindly provided by Dr. RJ 
Lefkowitz (Duke University Medical Center).  Troglitazone (Trog) was obtained from 
Calbiochem (San Diego, CA).  Ang II, isoproterenol and losartan were purchased from Sigma-
Aldrich (St. Louis, MO). 
 
Cell culture and pharmacological treatment.  HEK 293 cells stably expressing FLAG-tagged 
β1-adrenergic receptor (FLAG-β1AR cells) and HA-AT1AR cells were maintained in MEM 
supplemented with 10% FBS and 1% pen/strep at 37°C.  Cells were serum-starved for 1hr prior 
to drug treatments outlined in figure legends. 
 
Fluorescent microscopy.  HA-AT1AR cells were seeded into 35mm glass-bottom confocal 
dishes (MatTek Corporation, MA) coated with 10 µg/mL collagen (Sigma-Aldrich). After 5 min 
stimulation, cells were fixed with 4% paraformaldehyde/PBS for 20 min and permeabolized for 5 
min with ice-cold 0.2% Triton-X 100 in PBS. Cells were blocked for 1hr and all antibodies were 
diluted in 0.1% BSA in PBS. HA-AT1AR was visualized using monoclonal anti-HA clone HA-7 
(Sigma-Aldrich) at 1:1,000 overnight, 4Cْ, followed by goat anti-mouse IgG, Dylight594 
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(Thermo Scientific, Rockford IL) at 1:1000 for 1hr.  Samples were imaged using a Leica 
DMI6000B inverted microscope with the Leica DFC360 FX 1.4-megapixel monochrome digital 
camera. This system was controlled by and deconvolution carried out using Leica AF6000 
software. Each condition was performed independently 3 times. 
 
Chemical crosslinking and immunoprecipitation.  Crosslinking was performed as previously 
described [19].  Immunoprecipitation (IP) of samples was performed using 200 to 500 µg protein 
and overnight incubation at 4°C with 25 µL of monoclonal anti-HA agarose or anti-FLAG M2 
agarose (Sigma-Alrich).  βarr1/2 recruitment was normalized to total βarr1/2 levels and amount 
of immunoprecipitated HA-AT1AR or FLAG-β1AR.  
 
Immunoblotting.  Following drug treatment, cells were rinsed in ice-cold PBS then collected 
and lysed in buffer containing 1% NP40, 20mM Tris, pH 7.4, 137mM NaCl, 100µg/mL PMSF, 
10% Glycerol, 10mM NaF, 0.36mg/mL Na3VO4 and EDTA-free HALT protease inhibitor 
cocktail (Thermo Scientific, Rockford, IL).  Protein estimation was carried using Pierce 660nm 
Protein Assay Reagent (Thermo Scientific), and immunoblotting of samples performed as 
previously described [19].  The LI-COR biosciences Odyssey system was used for detection of 
immunoblots using anti-β-arrestin1/2 (D24H9) at 1:5,000 (Cell Signaling Technology, Danvers, 
MA) and anti-FLAG M2 at 1:10,000 (Sigma-Aldrich).  IRDye800 conjugated anti-HA epitope 
tag was used at 1:20,000 (Rockland, Gilbertsville, PA).  Non-conjugated primary antibodies 
were detected with IRDye680 Donkey anti-rabbit IgG (H+L) at 1:5,000 in Odyssey Blocking 
Buffer (LI-COR Biosciences, Lincoln, NE). 
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DAGR assay.  HA-AT1AR cells transfected with DAGR were seeded into 35mm glass-bottom 
confocal dishes (MatTek Corporation, MA) coated with 10 µg/mL fibronectin.  Prior to assay, 
cells were rinsed and incubated in buffer containing 125mM NaCl, 5mM KCl, 1.5mM MgCl2, 
1.5mM CaCl2, 10mM glucose, 0.2% BSA, 10mM HEPES, pH 7.4.  Cells were stimulated with 
drugs and underwent fluorescence resonance energy transfer (FRET) analysis as described 
previously [20], with quantification of the DAGR ratio over time calculated as FRET 
intensity/mCFP intensity, normalized to baseline. 
 
Cardiomyocyte Contractility 
Mice used in these studies were C57BL/6 mice and βarr2 knockout mice (described previously, 
[7; 21]), 3-6 months old and 25-40g. 10-15 cardiomyocytes were used per treatment per heart.  
Animals were handled according to approved protocols and animal welfare regulations of the 
Institutional Review Board at Duke University Medical Center.  Myocyte isolation, visualization 
and analysis were carried out as previously described [22; 23]. 
 
Statistical Analysis 
Data are presented as mean±s.e.m.  All statistical analyses were performed using One-way 
ANOVA with Tukey’s multiple comparisons test via Prism 5.0 software.   
 
Results  
Troglitazone induces AT1AR internalization and β-arrestin recruitment without activation 
of Gq protein.   
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 To determine if a PPARγ agonist can stimulate the AT1AR, we performed several assays 
to explore different facets of receptor activation.  A common response to 7TMR stimulation is 
internalization, thus we initially aimed to determine if the PPARγ agonist Trog induces AT1AR 
internalization.  HA-AT1AR cells were treated with Trog or Ang II, as a positive control for 
internalization, and HA-AT1AR puncta formation was assessed via immunofluorescence 
analysis.  HA-AT1AR puncta formation was increased in response to both Ang II and Trog (Fig. 
1, panels 2 and 3 arrowheads), indicating that the PPARγ agonist stimulates AT1AR 
internalization. 
Downstream effects of AT1AR activation are mediated by both Gq protein-dependent and 
βarr1/2-dependent signaling [24].  Gq protein activity can be assessed using DAGR, a fluorescent 
biosensor containing a diacylglycerol (DAG)  binding domain flanked by mCFP and mYFP that 
produces an increase in intermolecular FRET in response to DAG generation at the membrane 
[20].  HA-AT1AR cells expressing DAGR underwent stimulation with Trog, or Ang II as a 
positive control for Gq protein activation.  In response to Ang II, the FRET ratio increased 
sharply, indicating a rapid generation of DAG at the membrane (Fig. 2A) however stimulation 
with the same concentration of Trog (100µM) that induced AT1AR internalization did not 
increase DAG production, as shown by an unaltered FRET ratio.  These results indicate that, 
while Trog induces AT1AR internalization, it does not stimulate AT1AR-mediated Gq protein 
activity.   
Since βarr1/2 recruitment to activated AT1ARs is required for receptor internalization 
[24], we tested whether Trog acts to recruit endogenous βarr1/2 to the AT1AR.  HA-AT1AR cells 
were stimulated with increasing concentrations of Trog, or Ang II as a positive control for 
βarr1/2 recruitment, and underwent chemical crosslinking, immunoprecipitation of HA-AT1AR 
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and immunoblotting analysis.  Trog and Ang II each significantly increased βarr1/2 recruitment 
to HA-AT1AR in a concentration-dependent manner (Fig. 2B).  Concentrations of Ang II in the 
low nanomolar range (5-10nM) produced equivalent βarr1/2 recruitment elicited by 
concentrations of Trog in the high micromolar range (50-100µM), concentrations shown to 
induce AT1AR internalization (Fig. 1) and previously shown by others to mediate PPARγ-
independent effects [14; 25].  These data show that while Trog has no effect on AT1AR-coupled 
Gq protein activity, it does induce βarr1/2 recruitment to the AT1AR and promote receptor 
internalization. 
Troglitazone-mediated β-arrestin recruitment is selective for the AT1AR 
Trog-mediated βarr1/2 recruitment to the AT1AR suggests that Trog acts at the AT1AR 
itself to stimulate the response, thus we tested whether β-arrestin recruitment could be blocked 
with an ARB.  Using matched submaximal concentrations of Trog (50µM) and Ang II (5nM) for 
βarr1/2 recruitment, the ability of the ARB, losartan (Los), to block Trog-mediated βarr1/2 
recruitment to AT1AR was assessed via immunoprecipitation.  As a positive control for Los-
mediated inhibition of the AT1AR, Ang II-mediated βarr1/2 recruitment to HA-AT1AR was 
prevented by Los pretreatment (Fig. 3A).  Similarly, Trog-mediated βarr1/2 recruitment to HA-
AT1AR was ablated by pretreatment with Los.  These results indicate that Trog acts directly at 
the AT1AR to induce βarr1/2 recruitment, an effect that can be surmounted with an ARB.  
To investigate whether βarr1/2 recruitment in response to Trog is selective to the AT1AR 
or is a nonselective response to high concentrations of Trog at 7TMRs in general, we tested the 
ability of Trog to induce recruitment of βarr1/2 to the β1-adrenergic receptor (β1AR).   FLAG-
β1AR cells were stimulated with the highest concentration of Trog (100µM) shown to induce 
βarr1/2 recruitment to the AT1AR, or isoproterenol (ISO, 1µM) as a positive control for βarr1/2 
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recruitment to the β1AR.  While ISO stimulation induced a significant increase in βarr1/2 
recruitment to the β1AR, Trog was unable to promote β-arrestin recruitment to the β1AR (Fig. 
3B), indicating that Trog-induced βarr1/2 recruitment is selective for the AT1AR. 
 
Troglitazone increases cardiomyocyte contractility via the AT1AR in a β-arrestin-
dependent manner 
 To determine if a PPARγ agonist induces a physiologic effect mediated by AT1AR 
signaling, we measured the effect of Trog on the contractility of freshly isolated murine 
cardiomyocytes.  Treatment of wild-type cardiomyocytes with concentrations of Trog that were 
shown to induce βarr1/2 recruitment to AT1AR (50-100µM, Fig. 2B) resulted in a significant 
increase in both the percentage and rate of cell shortening (Fig. 4A, black bars).  These Trog-
mediated effects on contractility were statistically indistinguishable from those of Ang II.  
Importantly, the Trog-mediated increase in cardiomyocyte contractility was blocked by 
pretreatment with an ARB (valsartan, Val).  These results confirm our observation that Trog acts 
via the AT1AR and indicate that this interaction is capable of mediating a physiologic increase in 
cardiomyocyte contractility. 
 Since βarr2 plays a role in AT1AR-mediated myocyte contractility [7], we tested whether 
βarr2 signaling is required for Trog-mediated effects on myocyte contractility.  Cardiomyocytes 
isolated from βarr2 knockout mice (βarr2-KO) exhibited blunted cell shortening responses to 
both Ang II and Trog stimulation that were not statistically different from untreated cells (Fig. 
4A, grey bars).  To ensure that βarr2-KO cardiomyocytes were responsive to a contractile 
stimulus, they were treated with ISO, which produced a significant increase in contractile 
response.  Comparison of the contractility increases achieved in wild-type versus βarr2-KO 
 10 
cardiomyocytes revealed a significantly diminished response to both Ang II and Trog in the 




 In this study, we show that the PPARγ agonist Trog acts at the AT1AR to induce AT1AR 
internalization and ARB-sensitive recruitment of βarr1/2, in the absence of Gq protein activation.  
Moreover, we show that Trog increases cardiomyocyte contractility in an ARB-sensitive manner 
and is, at least partially, β-arrestin2-dependent.  Although PPARγ agonists classically activate 
PPARγ to mediate gene transcription, it has also been shown that these agents can exert PPARγ-
independent cell signaling processes [14; 15; 26].  Our observation that a PPARγ agonist acts at 
the AT1AR to rapidly recruit βarr1/2 suggests a lack of role for PPARγ-mediated transcriptional 
events in this process.  With regard to cardiomyocyte function, our data highlights the ability of 
Trog to induce an acute physiologic response via AT1AR signaling, increasing cardiomyocyte 
contractility.  These data, coupled with the ARB-sensitive nature of Trog-mediated AT1AR-β-
arrestin signaling, suggest that Trog-mediated effects at the level of AT1AR are independent of 
PPARγ activation.     
PPARγ agonists, including Trog and ciglitazone, have been previously reported to exert 
off-target effects, influencing intracellular processes independent of PPARγ activation in 
different cell lines and tissue [14; 15; 26].  One of these processes involved alterations in 
intracellular and/or extracellular Ca2+-handling, dependent upon the PPARγ agonist, though a 
role for AT1AR in this process was not explored [14].  Such effects on Ca2+-handling may 
explain our observation that a portion of the Trog-induced cardiomyocyte contractility was 
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βarr2-independent, as approximately half the contractile response remained in the absence of 
βarr2 (Fig. 4C).  In our study, we show Trog-mediated AT1AR effects are independent of Gq 
protein activation but dependent on β-arrestin recruitment.  The ability of a 7TMR to utilize β-
arrestin to exert downstream signaling is now being recognized as a mechanism to stimulate 
physiologic effects and accumulating data suggests that β-arrestin-mediated signaling opposes 
detrimental G protein-mediated activity to confer beneficial cellular effects [3; 6; 27]. 
 The ability of ligands to stabilize receptors in certain conformations that activate 
particular signaling pathways but not others has been increasingly explored [28; 29].  [Sar1, Ile4, 
Ile8]-Ang (SII) was shown to act at the AT1AR to preferentially enhance β-arrestin-mediated 
signaling with no effect on Gq protein activity and has been suggested to be more 
cardioprotective than conventional ARBs that prevent both G protein- and β-arrestin-dependent 
signaling [7; 19; 30].  Our study shows that the PPARγ agonist Trog acts similarly to SII by 
preferentially enhancing β-arrestin recruitment to AT1AR and subsequent cardiomyocyte 
contractility.  We postulate that PPARγ-mediated activation of AT1AR-β-arrestin signaling may 
in part provide an explanation for the cardioprotective effects of PPARγ agonists reported in the 
literature [8; 9; 10].  An additional benefit of PPARγ agonist action at the AT1AR may be the 
lack of potentially detrimental Gq protein-mediated signaling, especially under conditions of 
heightened Ang II stimulation, such as the development of hypertension.   Others have suggested 
that the use of SPARRMs to simultaneously block AT1AR activation and induce PPARγ activity 
would be clinically more beneficial than conventional PPARγ agonists by exerting both 
antihypertensive and antidiabetic effects [17; 18].  Alternatively, using Trog as an example, we 
suggest PPARγ agonists may show enhanced clinical usefulness by simultaneously inducing 
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beneficial PPARγ- and AT1AR-βarrestin-mediated effects without a concomitant increase in 
potentially detrimental AT1AR-Gq protein-mediated signaling.  
 
Conclusions 
 Our study shows that the PPARγ agonist Trog stimulates β-arrestin recruitment to the 
AT1AR and induces receptor internalization independent of Gq protein activity.  Effects of 
PPARγ agonists on acute cardiomyocyte function have not previously been reported, and here 
we show Trog increases cardiomyocyte contractility in a βarr2-dependent manner.  We propose 
that a PPARγ agonist with enhanced efficiency at inducing β-arrestin recruitment to the AT1AR, 
in the absence of Gq protein-mediated effects, could provide a means of potentiating the 
beneficial effects of both PPARγ agonists and ARBs in the treatment of cardiovascular ailments.  
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Figure 1:  The PPARγ agonist troglitazone increases AT1AR internalization.  HA-AT1AR 
cells stimulated with Ang II (100nM, panel 2) or Trog (100µM, panel 3) for 5 min underwent 
immunofluorescent analysis for HA-AT1AR localization.  Ang II and Trog stimulation each 
enhanced AT1AR internalization as indicated by the increased formation of HA-AT1AR-
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containing puncta (arrowheads), as compared to non-stimulated cells (NS, panel 1).  











Figure 2:  The PPARγ agonist troglitazone induces βarr1/2 recruitment to the AT1AR in a 
Gq protein-independent manner.  (A) FRET analysis was used to assess the Gq protein-
 17 
mediated response to agonist stimulation by detecting changes in the FRET ratio of transiently-
transfected DAGR in HA-AT1AR cells.  Ang II (100nM) stimulation induced a rapid increase in 
DAGR ratio which peaked at 90 sec, while Trog (100µM) stimulation produced no response in 
DAGR ratio, n = 3 independent experiments.  (B) HA-AT1AR cells were stimulated for 5 min 
with Ang II (1-10nM) or Trog (10-100µM) and underwent crosslink/IP with HA-agarose gel.  
βarr1/2 was recruited to HA-AT1AR in a concentration-dependent manner in response to both 
Ang II and Trog, as summarized in histogram.  *P<0.05, †P<0.01 and ‡ P<0.001 versus non-




Figure 3:  The PPARγ agonist troglitazone recruits β-arrestin to the AT1AR selectively.  (A) 
HA-AT1AR cells were stimulated with Ang II (5nM) ± Losartan (Los, 10µM) or Trog (50µM) ± 
 18 
Los (100µM) for 5 min and underwent crosslink/IP as described in Figure 2B.  βarr1/2 
recruitment to AT1AR was significantly increased following stimulation with either Ang II or 
Trog, an effect blocked by 5 min Los pretreatment, as summarized in histogram. †P<0.01 and ‡ 
P<0.001, n ≥ 3 each.  (B) FLAG-β1AR cells were stimulated with ISO (1µM) or Trog (100µM) 
for 5 min and underwent crosslink/IP with FLAG-M2 agarose.  βarr1/2 recruitment to β1AR was 
significantly increased following stimulation with ISO, but not Trog, as summarized in 






Figure 4:  The PPARγ agonist troglitazone induces AT1AR-β-arrestin-dependent 
cardiomyocyte contractility.  (A) Isolated wild-type or βarr2-KO cardiomyocytes were field-
stimulated at 0.5 Hz basally or following treatment with Ang II (10µM), Trog (50 or 100µM), 
Val (10µM) or ISO (1µM).  Histograms summarize % (upper) and rate (lower) of cardiomyocyte 
shortening.  †P<0.001 versus cells with no pharmacological treatment, n ≥ 3 individual hearts.  
(B) Comparison of the % change in contractility, relative to cells with no pharmacological 
treatment, in response to Ang II (10µM) or Trog (50 or 100µM) in wild-type versus βarr2-KO 
cardiomyocytes.  *P<0.05 versus wild-type within corresponding treatment group. 
